Myriad outlines $770M-$790M 2026 revenue and 66%-67% gross margin ranges while suspending adjusted EBITDA guidance (NASDAQ:MYGN)
· seekingalpha.com
Myriad Genetics (MYGN) Q2 2026 earnings call: revenue down 11%, guidance cut to $770-$790M, EBITDA guide pulled.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...